Harmony Biosciences Shares Fall After Q3 Earnings, Revenue Miss Estimates

09:42 AM EST, 11/04/2026 (MT Newswires) -- Harmony Biosciences (HRMY) shares fell more than 5% in early Wednesday trading after its Q3 earnings and net product revenue missed analyst estimates. The company reported Q3 earnings Wednesday of $0.81 per diluted share, down from $0.87 a year earlier. Analysts polled by FactSet expected $1.09. Net product revenue for the quarter ended Sept. 30 was $268.9 million, up from $239.5 million a year earlier. Analysts expected $272.1 million. The company said that as of Sept. 30, it had $1.05 billion in cash, cash equivalents and investments, up from $882.5 million as of Dec. 31, 2025. Harmony reiterated its 2026 WAKIX net revenue guidance of $1 billion to $1.04 billion. Analysts expect $1.03 billion. Price: 33.74, Change: -3.28, Percent Change: -8.86